Low-dose nivolumab leads to improved overall survival for head and neck cancer patients

Share :
Published: 19 Jul 2022
Views: 483
Dr Bishal Gyawali - Queen's University, Kingston, Canada

Dr Bishal Gyawali speaks to ecancer about the phase 3 randomised study evaluating the addition of low-dose nivolumab to palliative chemotherapy in head and neck cancer.

The study aimed to assess whether the addition of low-dose nivolumab to MC improved the overall survival of head and neck cancer patients. 

In this first-ever randomised study, the addition of low dose nivolumab led to improved overall survival and is an alternative standard of care for those who cannot access full dose nivolumab.